Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

Zachary R. Chalmers(Northwestern University), Garrett M. Frampton(Tech Foundation)

Genome Medicine

April 13, 2017

10.1186/s13073-017-0424-2

Cited by 3,717

Related Papers

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

|The Lancet|2016|3.7k

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

|Molecular Cancer Therapeutics|2017|2.4k

Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade

|Cancer Immunology Research|2016|493

Novel <i>SOX10</i> indel mutations drive schwannomas through impaired transactivation of myelination gene programs

|Neuro-Oncology|2023|31